Co-Diagnostics

228 articles about Co-Diagnostics

• Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event

  4/12/2024

  Co-Diagnostics, Inc. announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the City of South Salt Lake.

• Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

  4/4/2024

  Co-Diagnostics, Inc. today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).

• Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address

  3/21/2024

  Co-Diagnostics, Inc. announced that in his keynote address at the 5th Annual MarketsandMarkets conference in London, Company CEO Dwight Egan shared an update on the new manufacturing facilities in Salt Lake City, Utah and in Ranoli, India, including announcing the grand opening of the new Utah facility next month.

• Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England

  3/18/2024

  Co-Diagnostics, Inc. announced that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England.

• Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results

  3/14/2024

  Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.

• Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

  3/7/2024

  Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx") announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit.

• Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast

  2/29/2024

  Co-Diagnostics, Inc. announced today it will release its fourth quarter and full year 2023 financial results on Thursday, March 14, 2024 , after the market close.

• Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024

  2/1/2024

  Co-Diagnostics, Inc. announced the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company's vision.

• Co-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12

  1/3/2024

  Co-Diagnostics, Inc. announced that it will be hosting a booth next week at the 2024 Consumer Electronics Show from January 9-12 in Las Vegas, Nevada.

• Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

  12/27/2023

  Co-Diagnostics, Inc. announced that it has submitted its Co-Dx™ PCR COVID-19 test with Co-Dx PCR Pro™ instrument for review by the U.S. Food and Drug Administration for Emergency Use Authorization.

• Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023

  11/29/2023

  Co-Diagnostics, Inc. announced today that Co-Diagnostics will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York on November 30, 2023.

• Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

  11/9/2023

  Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023.

• Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development

  11/2/2023

  Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*.

• Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023

  10/31/2023

  Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx") announced today the list of events it has chosen to exhibit at or attend during November, 2023, which strategically align with its mission of increasing accessibility of affordable gold-standard PCR diagnostics around the world.

• Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast

  10/26/2023

  Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023, after the market close.

• Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25

  10/23/2023

  Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx") announced today that the Company will be hosting a booth this week at the Caribbean Association of Medical Technologies (CASMET) Scientific Symposium and BGM, held in Barbados October 22-26, 2023.

• Co-Diagnostics, Inc. to Host Booth at Medlab Africa 2023 in Johannesburg, South Africa

  10/16/2023

  Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 17-19, 2023.

• Co-Diagnostics, Inc. to Participate in the 2023 UHCA/UCAL Fall Convention & Expo on Sept 27-28

  9/27/2023

  Co-Diagnostics, Inc. announced that Co-Diagnostics will be sponsoring and participating in the Utah Health Care Association/Utah Center for Assisted Living Convention & Expo at the Mountain America Expo Center in Sandy, Utah on September 27-28, 2023.

• Co-Diagnostics, Inc. to Participate in 6th ACTC Conference in Skiathos, Greece

  9/22/2023

  Co-Diagnostics, Inc. announced today that Co-Diagnostics will be hosting a booth and presenting at the 6th Advances in Circulating Tumor Cells ("ACTC") conference.

• Co-Diagnostics, Inc. to Participate in Gilmartin Group Annual Emerging Growth Showcase on Sept 21

  9/21/2023

  Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Gilmartin Group Annual Emerging Growth Showcase.